Search

Your search keyword '"Gonzalez-Angulo, A M"' showing total 677 results
Start Over Author "Gonzalez-Angulo, A M"
677 results on '"Gonzalez-Angulo, A M"'

1. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

Author

Gonzalez-Angulo, Ana M, Krop, Ian, Akcakanat, Argun, Chen, Huiqin, Liu, Shuying, Li, Yisheng, Culotta, Kirk S, Tarco, Emily, Piha-Paul, Sarina, Moulder-Thompson, Stacy, Velez-Bravo, Vivianne, Sahin, Aysegul A, Doyle, Laurence A, Do, Kim-Anh, Winer, Eric P, Mills, Gordon B, Kurzrock, Razelle, and Meric-Bernstam, Funda

Subjects
Humans, Neoplasms, Breast Neoplasms, Neutropenia, Drug Eruptions, Hyperglycemia, Fatigue, Paclitaxel, Heterocyclic Compounds, 3-Ring, Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Drug Administration Schedule, Severity of Illness Index, Maximum Tolerated Dose, Adult, Aged, Middle Aged, Female, Male, Biomarkers, Tumor, Oncology & Carcinogenesis, Oncology and Carcinogenesis
Abstract

There is preclinical synergism between taxanes and MK-2206. We aim to determine the maximum tolerated dose, safety, and activity of combining MK-2206 and paclitaxel in metastatic cancer. Patients received weekly doses of paclitaxel at 80mg/m2 on day 1, followed by MK-2206 orally on day 2 escalated at 90mg, 135mg, and 200mg. Treatment continued until progression, excessive toxicity, or patient request. Blood and tissue were collected for pharmacokinetic and pharmacodynamics markers. A cycle consisted of three weeks of therapy. Dose-limiting toxicity (DLT) was defined as unacceptable toxicity during the first cycle. All statistical tests were two-sided. Twenty-two patients were treated, nine in dose escalation and 13 in dose expansion. Median age was 55 years. Median number of cycles was four. Dose escalation was completed with no DLT. CTCAE Grade 3 or higher adverse events were fatigue (n = 2), rash (n = 2), hyperglycemia (n = 1), and neutropenia (n = 7). Four patients in the expansion phase required MK-2206 dose reduction. Phase II recommended dose was established as paclitaxel 80mg/m2 weekly on day 1, and MK-2206 135mg weekly on day 2. Paclitaxel systemic exposure was similar in the presence or absence of MK-2206. Plasma MK-2206 concentrations were similar to data from previous phase I monotherapy. There was a statistically significant decrease in expression of pAKT S473 (P = .01) and pAKT T308 (P = .002) after therapy. PI3K/AKT/mTOR downregulation in tumor tissues and circulating markers did not correlate with tumor response or clinical benefit. There were five objective responses, and nine patients had stable disease. MK-2206 was well tolerated with paclitaxel. Preliminary antitumor activity was documented.

Published
2015

2. Functional consequence of the MET-T 1010I polymorphism in breast cancer

Author

Liu, Shuying, Meric-Bernstam, Funda, Parinyanitikul, Napa, Wang, Bailiang, Eterovic, Agda K, Zheng, Xiaofeng, Gagea, Mihai, Chavez-MacGregor, Mariana, Ueno, Naoto T, Lei, Xiudong, Zhou, Wanding, Nair, Lakshmy, Tripathy, Debu, Brown, Powel H, Hortobagyi, Gabriel N, Chen, Ken, Mendelsohn, John, Mills, Gordon B, and Gonzalez-Angulo, Ana M

Subjects
Genetics, Prevention, Cancer, Breast Cancer, Aetiology, 2.1 Biological and endogenous factors, Animals, Biomarkers, Tumor, Breast Neoplasms, Cell Line, Tumor, Cell Movement, Cell Proliferation, Female, Gene Frequency, Genetic Predisposition to Disease, Humans, Kaplan-Meier Estimate, Mice, SCID, Middle Aged, Neoplasm Invasiveness, Phenotype, Polymorphism, Single Nucleotide, Prognosis, Proto-Oncogene Proteins c-met, Time Factors, Transfection, Tumor Burden, Oncology and Carcinogenesis
Abstract

Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor receptor MET is potentially functionally altered due to an uncommon germline single nucleotide polymorphism (SNP), MET-T1010I, in many cancer lineages including breast cancer where the MET-T1010I SNP is present in 2% of patients with metastatic breast cancer. Expression of MET-T1010I in the context of mammary epithelium increases colony formation, cell migration and invasion in-vitro and tumor growth and invasion in-vivo. A selective effect of MET-T1010I as compared to wild type MET on cell invasion both in-vitro and in-vivo suggests that the MET-T1010I SNP may alter tumor pathophysiology and should be considered as a potential biomarker when implementing MET targeted clinical trials.

Published
2015

3. Functional consequence of the MET-T1010I polymorphism in breast cancer.

Author

Liu, Shuying, Meric-Bernstam, Funda, Parinyanitikul, Napa, Wang, Bailiang, Eterovic, Agda K, Zheng, Xiaofeng, Gagea, Mihai, Chavez-MacGregor, Mariana, Ueno, Naoto T, Lei, Xiudong, Zhou, Wanding, Nair, Lakshmy, Tripathy, Debu, Brown, Powel H, Hortobagyi, Gabriel N, Chen, Ken, Mendelsohn, John, Mills, Gordon B, and Gonzalez-Angulo, Ana M

Subjects
Cell Line, Tumor, Animals, Humans, Mice, SCID, Breast Neoplasms, Neoplasm Invasiveness, Genetic Predisposition to Disease, Prognosis, Tumor Burden, Transfection, Cell Proliferation, Cell Movement, Gene Frequency, Phenotype, Polymorphism, Single Nucleotide, Time Factors, Middle Aged, Female, Proto-Oncogene Proteins c-met, Kaplan-Meier Estimate, Biomarkers, Tumor, Biomarkers, Tumor, Cell Line, Mice, SCID, Polymorphism, Single Nucleotide, Oncology and Carcinogenesis
Abstract

Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor receptor MET is potentially functionally altered due to an uncommon germline single nucleotide polymorphism (SNP), MET-T1010I, in many cancer lineages including breast cancer where the MET-T1010I SNP is present in 2% of patients with metastatic breast cancer. Expression of MET-T1010I in the context of mammary epithelium increases colony formation, cell migration and invasion in-vitro and tumor growth and invasion in-vivo. A selective effect of MET-T1010I as compared to wild type MET on cell invasion both in-vitro and in-vivo suggests that the MET-T1010I SNP may alter tumor pathophysiology and should be considered as a potential biomarker when implementing MET targeted clinical trials.

Published
2015

4. Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study

Author

Vaz-Luis, Ines, Ottesen, Rebecca A, Hughes, Melissa E, Mamet, Rizvan, Burstein, Harold J, Edge, Stephen B, Gonzalez-Angulo, Ana M, Moy, Beverly, Rugo, Hope S, Theriault, Richard L, Weeks, Jane C, Winer, Eric P, and Lin, Nancy U

Subjects
Cancer, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Follow-Up Studies, Humans, Mastectomy, Segmental, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone, Trastuzumab, Treatment Outcome, Triple Negative Breast Neoplasms, United States, Receptor, erbB-2, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTreatment decisions for patients with T1a,bN0M0 breast cancer are challenging. We studied the time trends in use of adjuvant chemotherapy and survival outcomes among these patients.Patients and methodsThis was a prospective cohort study within the National Comprehensive Cancer Network Database that included 4,113 women with T1a,bN0M0 breast cancer treated between 2000 and 2009. Tumors were grouped by size (T1a, T1b), biologic subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, and receipt of chemotherapy with or without trastuzumab.ResultsMedian follow-up time was 5.5 years. Eight percent of patients with HR-positive/HER2-negative tumors were treated with chemotherapy. Fifty-two percent of those with HER2-positive or HR-negative/HER2-negative breast cancers received chemotherapy, with an increase over the last decade. Survival outcomes diverged by subtype and size, but the 5-year distant relapse-free survival (DRFS) did not exceed 10% in any subgroup. The 5-year DRFS for patients with T1a tumors untreated with chemotherapy ranged from 93% to 98% (n = 49 to 972), and for patients with T1b tumors, it ranged from 90% to 96% (n = 17 to 2,005). Patients with HR-positive/HER2-negative disease had the best DRFS estimates, and patients with HR-negative/HER2-negative tumors had the lowest. In this observational, nonrandomized cohort study, the 5-year DRFS for treated patients with T1a tumors was 100% for all subgroups (n = 12 to 33), and for patients with T1b tumors, it ranged from 94% to 96% (n = 88 to 241).ConclusionWomen with T1a,b tumors have an excellent prognosis without chemotherapy. Size and tumor subtype may identify patients in whom the rate of recurrence justifies consideration of chemotherapy. These patients represent an optimal group for evaluating less toxic adjuvant regimens to maintain efficacy while minimizing short- and long-term risks.

Published
2014

5. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer

Author

Gonzalez-Angulo, Ana M, Hennessy, Bryan T, Meric-Bernstam, Funda, Sahin, Aysegul, Liu, Wenbin, Ju, Zhenlin, Carey, Mark S, Myhre, Simen, Speers, Corey, Deng, Lei, Broaddus, Russell, Lluch, Ana, Aparicio, Sam, Brown, Powel, Pusztai, Lajos, Symmans, W Fraser, Alsner, Jan, Overgaard, Jens, Borresen-Dale, Anne-Lise, Hortobagyi, Gabriel N, Coombes, Kevin R, and Mills, Gordon B

Subjects
Cancer, Breast Cancer, Clinical Research, Biochemistry & Molecular Biology
Abstract

PurposeTo determine whether functional proteomics improves breast cancer classification and prognostication and can predict pathological complete response (pCR) in patients receiving neoadjuvant taxane and anthracycline-taxane-based systemic therapy (NST).MethodsReverse phase protein array (RPPA) using 146 antibodies to proteins relevant to breast cancer was applied to three independent tumor sets. Supervised clustering to identify subgroups and prognosis in surgical excision specimens from a training set (n = 712) was validated on a test set (n = 168) in two cohorts of patients with primary breast cancer. A score was constructed using ordinal logistic regression to quantify the probability of recurrence in the training set and tested in the test set. The score was then evaluated on 132 FNA biopsies of patients treated with NST to determine ability to predict pCR.ResultsSix breast cancer subgroups were identified by a 10-protein biomarker panel in the 712 tumor training set. They were associated with different recurrence-free survival (RFS) (log-rank p = 8.8 E-10). The structure and ability of the six subgroups to predict RFS was confirmed in the test set (log-rank p = 0.0013). A prognosis score constructed using the 10 proteins in the training set was associated with RFS in both training and test sets (p = 3.2E-13, for test set). There was a significant association between the prognostic score and likelihood of pCR to NST in the FNA set (p = 0.0021).ConclusionWe developed a 10-protein biomarker panel that classifies breast cancer into prognostic groups that may have potential utility in the management of patients who receive anthracycline-taxane-based NST.

Published
2011

6. Supplementary Figure 3 from PD-L1 Expression in Triple-Negative Breast Cancer

Author

Mittendorf, Elizabeth A., primary, Philips, Anne V., primary, Meric-Bernstam, Funda, primary, Qiao, Na, primary, Wu, Yun, primary, Harrington, Susan, primary, Su, Xiaoping, primary, Wang, Ying, primary, Gonzalez-Angulo, Ana M., primary, Akcakanat, Argun, primary, Chawla, Akhil, primary, Curran, Michael, primary, Hwu, Patrick, primary, Sharma, Padmanee, primary, Litton, Jennifer K., primary, Molldrem, Jeffrey J., primary, and Alatrash, Gheath, primary

Published
2023
Full Text
View/download PDF

8. Figure S4 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

Author

Liu, Shuying, primary, Li, Shunqiang, primary, Wang, Bailiang, primary, Liu, Wenbin, primary, Gagea, Mihai, primary, Chen, Huiqin, primary, Sohn, Joohyuk, primary, Parinyanitikul, Napa, primary, Primeau, Tina, primary, Do, Kim-Anh, primary, Vande Woude, George F., primary, Mendelsohn, John, primary, Ueno, Naoto T., primary, Mills, Gordon B., primary, Tripathy, Debu, primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 1 from PD-L1 Expression in Triple-Negative Breast Cancer

Author

Mittendorf, Elizabeth A., primary, Philips, Anne V., primary, Meric-Bernstam, Funda, primary, Qiao, Na, primary, Wu, Yun, primary, Harrington, Susan, primary, Su, Xiaoping, primary, Wang, Ying, primary, Gonzalez-Angulo, Ana M., primary, Akcakanat, Argun, primary, Chawla, Akhil, primary, Curran, Michael, primary, Hwu, Patrick, primary, Sharma, Padmanee, primary, Litton, Jennifer K., primary, Molldrem, Jeffrey J., primary, and Alatrash, Gheath, primary

Published
2023
Full Text
View/download PDF

10. Data from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 4 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 5 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 1 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 4 from PD-L1 Expression in Triple-Negative Breast Cancer

Author

Mittendorf, Elizabeth A., primary, Philips, Anne V., primary, Meric-Bernstam, Funda, primary, Qiao, Na, primary, Wu, Yun, primary, Harrington, Susan, primary, Su, Xiaoping, primary, Wang, Ying, primary, Gonzalez-Angulo, Ana M., primary, Akcakanat, Argun, primary, Chawla, Akhil, primary, Curran, Michael, primary, Hwu, Patrick, primary, Sharma, Padmanee, primary, Litton, Jennifer K., primary, Molldrem, Jeffrey J., primary, and Alatrash, Gheath, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from PD-L1 Expression in Triple-Negative Breast Cancer

Author

Mittendorf, Elizabeth A., primary, Philips, Anne V., primary, Meric-Bernstam, Funda, primary, Qiao, Na, primary, Wu, Yun, primary, Harrington, Susan, primary, Su, Xiaoping, primary, Wang, Ying, primary, Gonzalez-Angulo, Ana M., primary, Akcakanat, Argun, primary, Chawla, Akhil, primary, Curran, Michael, primary, Hwu, Patrick, primary, Sharma, Padmanee, primary, Litton, Jennifer K., primary, Molldrem, Jeffrey J., primary, and Alatrash, Gheath, primary

Published
2023
Full Text
View/download PDF

16. Data from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

Author

Liu, Shuying, primary, Li, Shunqiang, primary, Wang, Bailiang, primary, Liu, Wenbin, primary, Gagea, Mihai, primary, Chen, Huiqin, primary, Sohn, Joohyuk, primary, Parinyanitikul, Napa, primary, Primeau, Tina, primary, Do, Kim-Anh, primary, Vande Woude, George F., primary, Mendelsohn, John, primary, Ueno, Naoto T., primary, Mills, Gordon B., primary, Tripathy, Debu, primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

19. Suplpementary Table 2 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

20. Data from PD-L1 Expression in Triple-Negative Breast Cancer

Author

Mittendorf, Elizabeth A., primary, Philips, Anne V., primary, Meric-Bernstam, Funda, primary, Qiao, Na, primary, Wu, Yun, primary, Harrington, Susan, primary, Su, Xiaoping, primary, Wang, Ying, primary, Gonzalez-Angulo, Ana M., primary, Akcakanat, Argun, primary, Chawla, Akhil, primary, Curran, Michael, primary, Hwu, Patrick, primary, Sharma, Padmanee, primary, Litton, Jennifer K., primary, Molldrem, Jeffrey J., primary, and Alatrash, Gheath, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 3 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

22. Table S1 from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

Author

Liu, Shuying, primary, Li, Shunqiang, primary, Wang, Bailiang, primary, Liu, Wenbin, primary, Gagea, Mihai, primary, Chen, Huiqin, primary, Sohn, Joohyuk, primary, Parinyanitikul, Napa, primary, Primeau, Tina, primary, Do, Kim-Anh, primary, Vande Woude, George F., primary, Mendelsohn, John, primary, Ueno, Naoto T., primary, Mills, Gordon B., primary, Tripathy, Debu, primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Fig 2 from Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Author

Gonzalez-Angulo, Ana M., primary, Meric-Bernstam, Funda, primary, Chawla, Sant, primary, Falchook, Gerald, primary, Hong, David, primary, Akcakanat, Argun, primary, Chen, Huiqin, primary, Naing, Aung, primary, Fu, Siqing, primary, Wheler, Jennifer, primary, Moulder, Stacy, primary, Helgason, Thorunn, primary, Li, Shaoyi, primary, Elias, Ileana, primary, Desai, Neil, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure legend from Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Author

Gonzalez-Angulo, Ana M., primary, Meric-Bernstam, Funda, primary, Chawla, Sant, primary, Falchook, Gerald, primary, Hong, David, primary, Akcakanat, Argun, primary, Chen, Huiqin, primary, Naing, Aung, primary, Fu, Siqing, primary, Wheler, Jennifer, primary, Moulder, Stacy, primary, Helgason, Thorunn, primary, Li, Shaoyi, primary, Elias, Ileana, primary, Desai, Neil, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Fig 1 from Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Author

Gonzalez-Angulo, Ana M., primary, Meric-Bernstam, Funda, primary, Chawla, Sant, primary, Falchook, Gerald, primary, Hong, David, primary, Akcakanat, Argun, primary, Chen, Huiqin, primary, Naing, Aung, primary, Fu, Siqing, primary, Wheler, Jennifer, primary, Moulder, Stacy, primary, Helgason, Thorunn, primary, Li, Shaoyi, primary, Elias, Ileana, primary, Desai, Neil, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 1 from Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes

Author

Chavez-MacGregor, Mariana, primary, Liu, Shuying, primary, De Melo-Gagliato, Debora, primary, Chen, Huiqin, primary, Do, Kim-Anh, primary, Pusztai, Lajos, primary, Fraser Symmans, W., primary, Nair, Lakshmy, primary, Hortobagyi, Gabriel N., primary, Mills, Gordon B., primary, Meric-Bernstam, Funda, primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figures 1-3 from Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes

Author

Chavez-MacGregor, Mariana, primary, Liu, Shuying, primary, De Melo-Gagliato, Debora, primary, Chen, Huiqin, primary, Do, Kim-Anh, primary, Pusztai, Lajos, primary, Fraser Symmans, W., primary, Nair, Lakshmy, primary, Hortobagyi, Gabriel N., primary, Mills, Gordon B., primary, Meric-Bernstam, Funda, primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

34. Data from Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Author

Gonzalez-Angulo, Ana M., primary, Meric-Bernstam, Funda, primary, Chawla, Sant, primary, Falchook, Gerald, primary, Hong, David, primary, Akcakanat, Argun, primary, Chen, Huiqin, primary, Naing, Aung, primary, Fu, Siqing, primary, Wheler, Jennifer, primary, Moulder, Stacy, primary, Helgason, Thorunn, primary, Li, Shaoyi, primary, Elias, Ileana, primary, Desai, Neil, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

36. Data from Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer

Author

Miller, Todd W., primary, Pérez-Torres, Marianela, primary, Narasanna, Archana, primary, Guix, Marta, primary, Stål, Olle, primary, Pérez-Tenorio, Gizeh, primary, Gonzalez-Angulo, Ana M., primary, Hennessy, Bryan T., primary, Mills, Gordon B., primary, Kennedy, J. Phillip, primary, Lindsley, Craig W., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figures 1-8 from Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer

Author

Miller, Todd W., primary, Pérez-Torres, Marianela, primary, Narasanna, Archana, primary, Guix, Marta, primary, Stål, Olle, primary, Pérez-Tenorio, Gizeh, primary, Gonzalez-Angulo, Ana M., primary, Hennessy, Bryan T., primary, Mills, Gordon B., primary, Kennedy, J. Phillip, primary, Lindsley, Craig W., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Methods from Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer

Author

Miller, Todd W., primary, Pérez-Torres, Marianela, primary, Narasanna, Archana, primary, Guix, Marta, primary, Stål, Olle, primary, Pérez-Tenorio, Gizeh, primary, Gonzalez-Angulo, Ana M., primary, Hennessy, Bryan T., primary, Mills, Gordon B., primary, Kennedy, J. Phillip, primary, Lindsley, Craig W., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results